EHMT2 and pancreatic neoplasm: This leads us to propose a new oncogenic TSPAN1/FAM110A/HIST1H2BK/G9a axis in PDAC that is involved in the modulation of tumor progression and represents a novel therapeutic approach for pancreatic cancer treatment.